Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: billy d who wrote (867)	6/2/1998 5:52:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Well the last few days have been ugly. No news that I've seen, and although the biotechs and drug stocks have been weak, SEPR has been weaker. One possible guess to account for the weakness is that management has gotten more aggressive in developing its pipeline, and this has caused near-term earnings projections to deteriorate. With Wall Street's short-term focus this would be viewed as a negative, rather than the positive it really is. Of course it's possible that there's some nasty news lurking in the wings that we haven't got to hear about yet. Provided this isn't the case, SEPR remains far and away my favorite biotech on a risk-adjusted basis. BTW, according to reports from the annual meeting, there seems to be a new ICE on the SEPR bench. It's an improved version of Norvasc, a 2 billion dollar drug. I haven't heard in what respect it's improved. Peter